#ABOS

Leipziger Zeitung

@leipzigerzeitung.bsky.social

1 week ago

Nahrungsergänzungsmittel: Unerwünschte Abos und Inkasso-Karussell · Leipziger Zeitung In Ostsachsen häufen sich derzeit Fälle unerwünschter Post. Vor allem ältere Menschen erhalten Nahrungsergänzungsmittel der Unternehmen Naturnah und der

#Melder: #Nahrungsergänzungsmittel: Unerwünschte #Abos und #Inkasso-Karussell

www.l-iz.de/melder/wortm...
#Sachsen #Verbraucherzentrale

StockTitan

@stocktitan.net

1 week ago

Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026 Acumen Pharmaceuticals (NASDAQ: ABOS) will present one oral and two poster presentations at the AD/PD conference in Copenhagen, March 17–21, 2026. Presentations cover enhanced brain delivery (EBD™) of sabirnetug, sabirnetug biomarker responses (NULISA-Seq-TM), and novel AβO-targeting antibodies.The oral talk on March 21 details fusion of sabirnetug with an anti-transferrin receptor fragment; posters on March 17–18 cover biomarker analytics and antibody characterization. The oral data arise from an ongoing collaboration with JCR Pharmaceuticals using J-Brain Cargo® technology and support analytic plans for Phase 2 ALTITUDE‑AD.

#ABOS Acumen Pharmaceuticals to Showcase Advances in Alzheimer's Treatment at International Conference on Alzheimer’s and Parkinson’s Diseases 2026

www.stocktitan.net/news/ABOS/acumen-pharmac...

Björn

@funqr.chaos.social.ap.brid.gy

3 weeks ago

Welche Abos habt ihr? Bei mir sind es die zwei monatlichen Zeitschriften der Stiftung Warentest, der Rundfunkbeitrag, mein Jobticket, Software wie CrossOver und Proxmox und meine Bibliotheksmitgliedschaft.

Wer seinen Rundfunkbeitrag optimal nutzen möchte, kann sich mal den Account von […]

TrueDarkness35

@truedarkness35.bsky.social

1 month ago

Warum Netflix gerade boykottiert wird! YouTube video by Meunooo

Bitte #kündigt eure #Abos bei Netflix 👀

Unterstützt bitte unsere deutschen Synchronsprecher und keine #Ki von Netflix.

Wenn Netflix damit durch kommt, werden es andere dann auch probieren.

#Boykottiert #Netflix für unsere #Synchronsprecher 👀

youtu.be/Kd7n3dXsL78?...

TrueDarkness35

@truedarkness35.bsky.social

1 month ago

Ganz offiziell: Wie Netflix gerade unsere Synchron-Legenden ersetzt YouTube video by Andrew

Bitte #kündigt eure #Abos bei Netflix ❗️

Unterstützt bitte unsere deutschen Synchronsprecher und keine #Ki von Netflix.

Wenn Netflix damit durch kommt, werden es andere dann auch probieren.

#Boykottiert #Netflix für unsere #Synchronsprecher 👀

youtu.be/97U-LjuQ1A8?...

das nd

@nd-aktuell.de

2 months ago

Es ist ein Tisch mit nd Zeitungen und Werbematerialien zu sehen.

Das #nd ist wirtschaftlich bedroht und kämpft ums Überleben.
Wir bitten euch daher um dauerhafte Unterstützung durch #Abos und
Spenden.

👉🏼 genossenschaft.nd-aktuell.de/spenden
Abos:
👉🏼 www.nd-aktuell.de/abo/

Michael Blume

@blumeevolution.sueden.social.ap.brid.gy

3 months ago

„Microsoft hat eine signifikante #Preiserhöhung für Microsoft 365 angekündigt. Ab Juli 2026 werden die Preise einiger Lizenzen um bis zu 25 Prozent angehoben. Das gilt für die Business-#Abos von Microsoft 365 und für E- und F-#Lizenzen in Office 365.“

Ich wäre auch aus Gründen von #Sicherheit […]

StockTitan

@stocktitan.net

3 months ago

Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease Acumen Pharmaceuticals (NASDAQ: ABOS) announced on Nov 17, 2025 that the first participant was dosed in the open-label extension (OLE) of its Phase 2 ALTITUDE-AD trial of sabirnetug (ACU193) in people with early Alzheimer’s disease.The OLE offers participants who completed the 18-month placebo-controlled portion additional dosing of 35 mg/kg IV every four weeks for 52 weeks. Clinical measures and safety monitoring remain the same. The company cited Phase 1 INTERCEPT-AD results showing favorable safety, low ARIA-E rates, target engagement, and biomarker effects including amyloid plaque reduction at highest doses. Acumen expects topline ALTITUDE-AD results in late 2026.

#ABOS Acumen Pharmaceuticals Announces First Participant Dosed in Phase 2 Open-Label Extension Study of Sabirnetug in People with Early Alzheimer’s Disease

www.stocktitan.net/news/ABOS/acumen-pharmac...

StockTitan

@stocktitan.net

4 months ago

Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights Acumen Pharmaceuticals (NASDAQ: ABOS) reported Q3 2025 results and a business update on Nov. 12, 2025. The company had $136.1 million in cash, cash equivalents and marketable securities as of Sept. 30, 2025, which it expects will support operations into early 2027. Acumen continues its Phase 2 ALTITUDE-AD study of sabirnetug (ACU193) and began dosing the open-label extension in Nov. 2025. The company expects non-clinical data for its Enhanced Brain Delivery program in early 2026 and Phase 2 topline results for ALTITUDE-AD in late 2026. Q3 R&D expense was $22.0M and net loss was $26.5M.

#ABOS Acumen Pharmaceuticals Reports Third Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ABOS/acumen-pharmac...

Hunteress

@hunteress.eurosky.social

4 months ago

Regionalisierungsgesetz: Bundestag sichert Finanzierung des Deutschlandtickets bis 2030 Bund und Länder teilen sich bis 2030 die Kosten für die Absicherung des Deutschlandtickets. Der Preis für die Abonnenten soll ab 2027 über einen Index festgelegt werden.

"Derzeit nutzen rund 14 Millionen Menschen das Ticket. Es war 2023 mit 49 Euro gestartet. Für die regionalen Verkehrsverbünde ist das #Deutschlandticket ein Verlustgeschäft, denn viele #Abos für #Pendler waren zuvor deutlich teurer."

1/2

www.zeit.de/mobilitaet/2...

gregor withalm

@grewit.bsky.social

4 months ago

"Spar´ Geld - Graz borgt´s Dir" #Graz #VandenBerg #Stadtbibliothek #Mediathek #Dingeborg #Treffpunkt #Werkzeug #Bohrmaschine #Freizeit #StandUpPaddle #Abos #nachhaltig #sozial #ElisabethHamann #Kanal3TV #R9Austria #Stadtgespräch
www.youtube.com/watch?v=PjO3...

Small Cap Strategist

@smcapstrategist.bsky.social

5 months ago

Small-cap stocks with declining money flow, Mon Sept 22nd - #FISI #EQ #DFDV #CGTX #BETR #ABOS #TWI #UTL #SDHC #RFI #PSFE #VTSI #MAGN #LZB #HOUS #GMRE #FBRT #ETD #DX #CHMI #BBT #ARR - More: crystalequityresearch.com/leading-indi... - #smallcap

Ahmet BÜTÜN

@ahmetbutun.bsky.social

6 months ago

States Heading Toward Constitutional Showdown Over Abortion Shield Laws Texas and New York are at the leading edge of an escalating states’ rights battle over the mailing of abortion pills to patients in states with bans.. @cosmicmeta.ai #Abos

https://u2m.io/glyfSZHf

StockTitan

@stocktitan.net

7 months ago

Acumen Reports Strong $166M Cash Position, Cuts Alzheimer's Trial Costs 40% with Innovation Acumen strengthens Alzheimer's pipeline with $166.2M cash runway, reports 40% trial cost reduction, and advances Phase 2 study. See full financial details.

#ABOS Acumen Pharmaceuticals Reports Second Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ABOS/acumen-pharmac...

☯︎ Kamui Sanka ⛩️🏳️‍🌈

@kamuisanka.bsky.social

7 months ago

Drucker im Abo-System? #kamui_sanka #vtuber #drucker #abos YouTube video by Kamui Sanka

Drucker im Abo-System? #kamui_sanka #vtuber #drucker #abos youtu.be/pawd6L0xwgY?...

#gervtuber #vtuber #pngtuber #drucker #deutsch

cargobike.bsky.social - Sharing brings bandwith in bsky!

@cargobike.bsky.social

7 months ago

"Mimimi, wir haben nur von der #dpa abgeschrieben, da können wir nichts für die Inhalte..." war auch der Grund für die dauerhafte Kündigung des #Abos von @zeit.de . Gerade die Tage dem Abonnenten-Rückhol-Callcenter-Agent erklärt, dass das nicht geht.

Small Cap Strategist

@smcapstrategist.bsky.social

7 months ago

Small-cap stocks with strong volume declines, Tue Jul 15th - #RPTX #MSPR #KOD #GDC #CENN #BACQ #ABOS #STC #FBK #EQBK #RVYL #VBTX - More: crystalequityresearch.com/SmCpStr/ - #smallcap

StockTitan

@stocktitan.net

8 months ago

Revolutionary Alzheimer's Treatment: Acumen and JCR Join Forces on Brain-Penetrating Drug Technology New collaboration combines Acumen's oligomer antibodies with JCR's brain barrier technology for enhanced Alzheimer's treatment. See development timeline.

#ABOS Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease

www.stocktitan.net/news/ABOS/acumen-pharmac...

David De La Fuente

@armonia03.bsky.social

9 months ago

Verified, recertified, and blessed ✨
American Board of Sexology ✔️
& my manuscript on trans wellbeing + justice caught the eye of the American Journal of Orthopsychiatry 🌈📚
#QueerScholar #TransResearch #PrideInPractice #ABoS #RadiantMinds #davidsfountainofthought

StockTitan

@stocktitan.net

10 months ago

Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights Acumen Pharmaceuticals (NASDAQ: ABOS) reported its Q1 2025 financial results and business updates. The company's Phase 2 ALTITUDE-AD study investigating sabirnetug (ACU193) for early Alzheimer's disease treatment is fully enrolled with 542 participants, with topline results expected in late 2026. Financial highlights include cash position of $197.9 million as of March 31, 2025, expected to fund operations into early 2027. Q1 2025 saw increased R&D expenses of $25.3 million (vs $12.4 million in Q1 2024) due to ALTITUDE-AD trial costs, while G&A expenses slightly decreased to $5.1 million. The company reported a net loss of $28.8 million for Q1 2025, compared to $14.9 million in Q1 2024. Recent developments include presentations at AD/PD conference highlighting plasma pTau217 assay results and other research findings.

#ABOS Acumen Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Highlights

www.stocktitan.net/news/ABOS/acumen-pharmac...

Linz News

@linznews.bsky.social

10 months ago

🧐 Regenwetter!
🙄 Im Trockenen unter der Unionkreuzung sind augenscheinlich "Vermarktungsspezialisten" für Spenden, Abos oder Mitgliedschaften aktiv.
👉 Nebst Fahrschein braucht es heute also auch noch starke Nerven ...
📸 Leserfoto

#regen #bim #ubahn #omg #what #abos #linz #lesernews

StockTitan

@stocktitan.net

11 months ago

Game-Changing Trial Screening Method: Acumen Advances Alzheimer's Research with pTau217 Innovation New screening strategy reduces costly PET scans in Alzheimer's trials. Acumen showcases promising neuronal model results and biomarker developments. Full analysis inside.

#ABOS Acumen Pharmaceuticals Showcases pTau217 Trial Screening Progress in Phase 2 ALTITUDE-AD Trial and Preclinical Research Methods at AD/PD 2025 and AAN Annual Meeting

www.stocktitan.net/news/ABOS/acumen-pharmac...

StockTitan

@stocktitan.net

11 months ago

Acumen's $231M War Chest Powers Breakthrough Alzheimer's Drug Development Strong financial position funds operations through 2027 as Acumen advances late-stage Alzheimer's treatment. Phase 2 enrollment complete, promising Phase 1 data revealed.

#ABOS Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2024 and Business Highlights

www.stocktitan.net/news/ABOS/acumen-pharmac...

StockTitan

@stocktitan.net

11 months ago

Breakthrough Alzheimer's Treatment Advances: Phase 2 Trial Fills Ahead of Schedule Novel antibody therapy shows promise in early Alzheimer's. First-in-class treatment targeting toxic oligomers enrolls 542 patients across global sites. Full analysis inside.

#ABOS Acumen Pharmaceuticals Completes Enrollment of ALTITUDE-AD, a Phase 2 Clinical Trial of Sabirnetug (ACU193) in Early Alzheimer’s Disease

www.stocktitan.net/news/ABOS/acumen-pharmac...

StockTitan

@stocktitan.net

11 months ago

Breakthrough in Alzheimer's Treatment: Acumen's New Injectable Drug Shows Promise in Phase 1 Sabirnetug's subcutaneous formulation demonstrates positive safety profile and exposure levels, advancing Acumen's innovative approach to targeting amyloid beta in Alzheimer's treatment.

#ABOS Acumen Pharmaceuticals Announces Topline Results from Phase 1 Study of Subcutaneous Formulation of Sabirnetug in Healthy Volunteers

www.stocktitan.net/news/ABOS/acumen-pharmac...